Lucentis promising hopes for retinal vein occlusion in Phase III trial

6556611700324611Genentech, Inc. announced recently that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion.

Full article »


Protected by Comment Guard Pro